The VEGF-A-directed antibody Bevacizumab is currently approved for use in combination chemotherapeutic regimens as the first and second line of treatment in colorectal cancer and as the first-line treatment in lung cancer [54]. This evidence concerns the gene VEGFA and lung carcinoma.